Meningococcal polysaccharide vaccine group Y

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Menquadfi, Menveo, Nimenrix
Generic Name
Meningococcal polysaccharide vaccine group Y
DrugBank Accession Number
DB13888
Background

Meningococcal group Y polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup Y. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

Type
Biotech
Groups
Approved, Experimental, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Meningococcal polysaccharide antigen group Y
  • Neisseria meningitidis group Y capsular polysaccharide antigen
  • Neisseria meningitidis group Y polysaccharide antigen, A

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofInvasive meningococcal infection caused by neisseria meningitidis serogroup y••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETMeningococcal polysaccharide vaccine group Y (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2012-11-07Not applicableTurkey flag
MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETMeningococcal polysaccharide vaccine group Y (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
MENACTRA®Meningococcal polysaccharide vaccine group Y (4 mcg) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (48 mcg) + Meningococcal polysaccharide vaccine group C (4 mcg) + Meningococcal polysaccharide vaccine group C (4 mcg) + Meningococcal polysaccharide vaccine group W-135 (4 mcg)SolutionIntramuscularSANOFI AVENTIS DE COLOMBIA S.A2010-02-122018-08-29Colombia flag
MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADETMeningococcal polysaccharide vaccine group Y (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group W-135 (50 mcg/0.5ml)Injection, powder, for solutionSubcutaneousPFİZER PFE İLAÇLARI A.Ş.2020-08-142019-07-01Turkey flag
MenhibrixMeningococcal polysaccharide vaccine group Y (5 ug/0.5mL) + Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL)KitIntramuscularGlaxoSmithKline Biologicals SA2013-09-032017-09-17US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
CBZ4BH7TJ1
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911457
RxNav
314725
FDA label
Download (83.9 KB)

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4Active Not RecruitingPreventionPapilloma Viral Infection1somestatusstop reasonjust information to hide
4CompletedBasic ScienceMeningitis / Meningococcal Disease / Septicemia1somestatusstop reasonjust information to hide
4CompletedOtherMeningococcal Meningitis1somestatusstop reasonjust information to hide
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1somestatusstop reasonjust information to hide
4CompletedPreventionDiphtheria / Meningitis / Meningococcal sepsis / Pertussis / Tetanus1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
SolutionIntramuscular
Injection, powder, for solutionSubcutaneous
Injection, powder, lyophilized, for solutionIntramuscular
KitIntramuscular
Injection; kitSubcutaneous
Kit; powder, for solutionSubcutaneous
Powder, for solutionSubcutaneous
PowderIntramuscular
Powder, for solution; solutionIntramuscular
Injection, powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular10 mcg/0.5ml
Kit; powder, for solutionIntramuscular
Injection, powder, for solution
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 08, 2017 20:22 / Updated at June 12, 2020 16:53